Company Profile
Ascendis Pharma Stock Price, News & Catalysts
- Ticker:
- ASND
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Denmark
Stock performance
253.29 USD (-0.60%)
Close
Last updated: August 21, 2026
13.4B USD
Market cap
Why the stock is moving
As of Aug 21, 2026, ASND closed down 0.60% at $253.29. No new same-company headline was identified in the current news window.
Company overview
TransCon Technology
Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology.
Commercial Endocrinology Portfolio
YORVIPATH is a parathyroid-hormone replacement therapy for chronic hypoparathyroidism. SKYTROFA is a once-weekly growth-hormone therapy, and YUVIWEL is approved in the United States for children with achondroplasia.
Growth-Disorder Development
Ascendis is studying TransCon CNP in infants with achondroplasia and in hypochondroplasia. It is also evaluating TransCon CNP combined with TransCon hGH to address growth and skeletal complications.
Oncology Program
Onvapegleukin alfa is a long-acting IL-2 beta/gamma agonist in Phase 1/2 development, including combination treatment for platinum-resistant ovarian cancer.
Future catalysts
- European regulatory decision for YUVIWEL in the fourth quarter of 2026.
- Initiation of a Phase 3 TransCon CNP study in hypochondroplasia in the second half of 2026.
- Initiation of a Phase 3 TransCon CNP plus TransCon hGH study in pediatric achondroplasia in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ascendis Pharma (ASND)?
Ascendis Pharma (ASND) most recently closed at 253.29 USD, a -0.60% move versus the previous session.
What is the market cap of Ascendis Pharma (ASND)?
Ascendis Pharma currently has a market capitalization of 13.4B USD on BioPharmSignal.
What does Ascendis Pharma do?
TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic hypoparathyroidism. SKYTROFA...
On which exchange is ASND stock listed?
Ascendis Pharma (ASND) is associated with NASDAQ, Denmark, Biopharma.
What is IL-2?
Oncology Program Onvapegleukin alfa is a long-acting IL-2 beta/gamma agonist in Phase 1/2 development, including combination treatment for platinum-resistant ovarian cancer.
Which conditions is Ascendis Pharma targeting with IL-2?
Ascendis Pharma is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Ascendis Pharma describe recent progress with IL-2?
European regulatory decision for YUVIWEL in the fourth quarter of 2026. Initiation of a Phase 3 TransCon CNP study in hypochondroplasia in the second half of 2026. Initiation of a Phase 3 TransCon CNP plus TransCon hGH study in pediatric achondroplasia in the fourth quarter of 2026.
What is TransCon?
TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time.